Title: Antimicrobial Development in the Era of Emerging Resistance
Volume: 9
Issue: 8
Author(s): Antonio Sorlozano, Cristina Carrasco, Jose Cabeza, Enrique Villegas and Jose Gutierrez
Affiliation:
Keywords:
Faropenem, dalbavancin, telavancin, oritavancin, ceftobiprole, iclaprim
Abstract: Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.